The putative modular polyketide synthase (PKS) that prescribes biosynthesis of the bryostatin natural products from the uncultured bacterial symbiont of the marine bryozoan Bugula neritina possesses a discrete open reading frame (ORF) (bryP) that encodes a protein containing tandem acyltransferase (AT) domains upstream of the PKS ORFs. BryP is hypothesized to catalyze in trans acylation of the PKS modules for polyketide chain elongation. To verify conservation of function, bryP was introduced into AT-deletion mutant strains of a heterologous host containing a PKS cluster with similar architecture, and polyketide production was partially rescued. Biochemical characterization demonstrated that BryP catalyzes selective malonyl-CoA acylation of native and heterologous acyl carrier proteins and complete PKS modules in vitro. The results support the hypothesis that BryP loads malonyl-CoA onto Bry PKS modules, and provide the first biochemical evidence of the functionality of the bry cluster.
INTRODUCTION
Evidence is mounting that many bioactive natural products isolated from marine invertebrates (e.g., sponges, ascidians, bryozoans) are produced by microbial symbionts (reviewed by Konig et al. [2006] , Piel [2004] , and Salomon et al. [2004] ). Particularly compelling evidence indicates that the bryostatins, ecologically relevant bioactive compounds isolated from the temperate marine bryozoan, Bugula neritina, are produced by the uncultured microbial symbiont ''Candidatus Endobugula sertula'' that resides in B. neritina (Davidson et al., 2001; Lopanik et al., 2004b; Lopanik et al., 2006b) . To date, different populations of B. neritina-''Ca. Endobugula sertula'' have yielded 20 different bryostatins (Lopanik et al., 2004a; Pettit, 1996) . Each of these molecules bears an identical polyketide core, but is distinguished by its pendant acyl groups at two positions in the bryolactone ring system. The pharmacological activity of bryostatin 1 has been extensively studied; it has been shown to activate protein kinase C (reviewed by Mutter and Wills [2000] ) and exhibits anticancer activity, as well as promise against neurodegenerative disorders, including Alzheimer's disease (Etcheberrigaray et al., 2004; Sun and Alkon, 2005) . To date, the National Cancer Institute lists 38 completed, ongoing, or planned clinical trials using bryostatin 1 as a single or combination therapeutic, and its importance as a molecular probe to understand specific neurological disorders is also increasing.
Recently, the 77 kb biosynthetic gene cluster (bry) that is putatively responsible for assembly and tailoring of the bryostatins was cloned and sequenced from two geographically distinct sibling species of ''Ca. Endobugula sertula''/B. neritina (Figure 1A) (Davidson and Haygood, 1999; Hildebrand et al., 2004; Sudek et al., 2007) . The bry genes from the deep-water California (CA) sibling species are positioned on at least two loci of the chromosome, while the gene cluster from the shallow-water North Carolina (NC) sibling species appears to reside on a contiguous fragment of DNA. All evidence suggests that bry encodes the enzymes necessary for bryostatin biosynthesis, but, as ''Ca. Endobugula sertula'' has been refractory to cultivation efforts, gene disruption and complementation have not been possible. Portions of bry have been shown by PCR to be absent in antibiotic-cured B. neritina (Davidson et al., 2001; Lopanik et al., 2006a) , and colocalization of 16S rRNA of ''Ca. Endobugula sertula'' and a fragment of the PKS genes using in situ hybridizations on B. neritina larvae (Davidson et al., 2001 ) provide evidence for their bacterial origin. Moreover, analysis of PKS fragments amplified from B. neritina-derived ''Ca. Endobugula sertula'' metagenome samples revealed that bry is the only biosynthetic locus large enough to specify assembly of bryostatin metabolites (Davidson et al., 2001) .
Bacterial type I PKSs are large multifunctional enzymes that produce complex polyketide molecules in an assembly line manner (reviewed by Fischbach and Walsh [2006] ). The group of enzymatic domains responsible for one chain elongation step is termed a module. Three enzymatic domains comprise a minimal module in PKS biosynthesis: the acyltransferase (AT), the acyl carrier protein (ACP), and the ketosynthase (KS). The AT catalyzes covalent linkage of the CoA-activated extender unit onto the ACP, and the KS domain catalyzes condensation of each extender unit, resulting in elongation of the polyketide chain by two carbons. Often, there are additional domains within a module, termed b-keto processing domains, which act to modify the b-carbonyl, the ketoreductase (KR), the dehydratase (DH), and the enoyl reductase. After full extension and reduction of the polyketide chain, it is released in either a cyclized or linear form, typically catalyzed by a thioesterase domain operating at the end of the pathway. Following release from the PKS, the natural product can be further modified by tailoring enzymes, such as oxygenases, methyltransferases (MTs), and glycosyltransferases (reviewed by Rix et al. [2002] ).
One significant feature of the putative bryostatin PKS is the absence of AT domains within the polypeptides. Instead, a single ORF (bryP) encoding two AT domains is present directly upstream of the PKS genes in the NC-derived gene cluster (Figure 1A) (Sudek et al., 2007) . There are several other PKS and hybrid PKS/nonribosomal peptide synthetase (NRPS) clusters that have discrete AT domains (termed ''trans-AT''), including leinamycin (Cheng et al., 2003) , lankacidin (Mochizuki et al., 2003) , mupirocin ( Figure 1B ) (El-Sayed et al., 2003) , pederin (Piel, 2002) , onnamide (Piel et al., 2004), rhizoxin (Partida-Martinez and Hertweck, 2007) , mycosubtilin (Duitman et al., 1999) , myxovirescin (Simunovic et al., 2006) , virginamycin M (Pulsawat et al., 2007) , difficidin (Chen et al., 2006) , macrolactin (Chen et al., 2006; Schneider et al., 2007) , and bacillaene (Butcher et al., 2007; Moldenhauer et al., 2007) . In these AT-less modules, there are well-defined remnants of AT domains that are hypothesized to aid in docking of the trans-AT protein, although this has yet to be confirmed experimentally (Nguyen et al., 2008; Tang et al., 2004) . The first in vitro experiment demonstrating that a trans-AT is able to load malonyl-CoA onto excised ACPs was performed with the discrete AT (LmnG) and ACPs from the leinamycin gene cluster (Cheng et al., 2003) . Furthermore, LmnG was shown to load malonyl-CoA onto a tridomain portion of LmnJ (DH-ACP-KR). Subsequent studies have shown that discrete ATs are able to load malonyl-CoA onto cognate discrete and excised ACPs (Calderone et al., 2006 . It is proposed by Nguyen et al. (2008) that discrete AT domains act in trans, loading the extender unit onto the ACP of the AT-less module, but this has yet to be demonstrated in vitro with a complete native PKS module. (Sudek et al., 2007) . Enzymatic domains overexpressed in this study are zoomed. Modules putatively responsible for the portions of the bryostatin precursor, ''bryostatin 0,'' are noted. (B) Mupirocin (PA) gene cluster from P. fluorescens NCIMB 10586 (El-Sayed et al., 2003) . Scale bar, 1 kbp for (A) and (B).
In addition to bry, several other PKS and PKS/NRPS gene clusters encode multiple discrete AT domains. The pederin system from the microbial symbiont of the beetle Paederus fucipes has two AT domains on two different ORFs (Piel, 2002) , while the bacillaene gene cluster from two Bacillus species has three AT domains on three different ORFs (Butcher et al., 2007; Chen et al., 2006; Moldenhauer et al., 2007) . The bryostatin gene cluster has two AT domains encoded on a single ORF (BryP), and several other gene clusters also have trans-AT didomain ORFs, including the mupirocin gene cluster from Pseudomonas fluorescens (mmpC) (El-Sayed et al., 2003) , the myxovirescin gene cluster from Myxococcus xanthus (taV) (Simunovic et al., 2006) , and the rhizoxin gene cluster from Burkholderia rhizoxina (rhiG) (Partida-Martinez and Hertweck, 2007) . Gene disruption studies of the complete didomain were performed for both taV (Simunovic et al., 2006) and rhiG (Partida-Martinez and Hertweck, 2007) , and, in both cases, secondary metabolite production was completely abolished. Similarly, when the second AT domain of MmpC (AT 2 ) was deleted from the genome of P. fluorescens, no mupirocin was detected in the supernatant of the mutant strain (El-Sayed et al., 2003) . Upon complementation with a plasmid bearing mmpC, mupirocin production was restored to wild-type levels, demonstrating the necessity of MmpC AT 2 for mupirocin biosynthesis. Although it is clear that the trans-AT domains are required for biosynthesis, the purpose of two AT domains on a single ORF remains enigmatic.
In this article, we explore the substrate specificity of BryP in vivo and in vitro. Mono-and didomain constructs of BryP were introduced into P. fluorescens mmpC AT 1 and AT 2 deletion mutants, and restoration of mupirocin production for one AT resulted. We investigated the substrate specificity in vitro by assessing the ability of the bryP-encoded AT mono-and didomains to transfer malonyl-or methylmalonyl-CoA to a variety of carrier proteins from the bryostatin PKS and other heterologous PKS and NRPS systems. We demonstrate that BryP is able to transfer malonylCoA onto the ACP domain of a full native module from the bryostatin PKS. Furthermore, to our knowledge, this work represents the first example of biochemical studies on enzymes from a microbial symbiont-derived natural product biosynthetic pathway.
RESULTS AND DISCUSSION
Sequence and Phylogenetic Analysis of BryP AT 1 and AT 2 The DNA sequences of the shallow-water NC and deep-water CA AT didomain bryP are 98.5% identical, and the corresponding amino acid sequences are 96.8% identical (98.4% similar). BryP AT 1 and AT 2 from shallow-water NC populations share only 25.9% identity with each other at the amino acid level, but both domains contain the necessary signature sequences found in functional ATs from fatty acid and polyketide synthases (see Figure S1 available online). Notably, the N-terminal (P/S/T) GQGSQ loop that makes up one side of the active site binding cleft is present in both BryP AT 1 (residues 8-13) and BryP AT 2 (322-327). Additionally, the catalytic dyad (Ser-His) is present in both domains. Considerable investigation during the past few years (Petkovic et al., 2008; Reeves et al., 2001 ) has enabled prediction of the substrate preference for each AT domain, and an ability to correlate selectivity to key amino acid motifs. Based on multiple sequence alignments, BryP AT 1 shares all characteristics of a malonyl-CoA-specific AT ( Figure S1 ). BLAST analysis revealed that BryP AT 1 is most similar to the PksC AT domain from the bacillaene gene cluster in Bacillus subtilis subsp. subtilis str. 168 (NP_389591; e value = 8 3 10
À77
; 55% identity), and to BaeC from Bacillus amyloliquefaciens FZB42 (YP_001421285; e value = 2 3 10 À76 ; 54% identity). BryP AT 2 is most similar to an AT domain identified in the genome sequence of Clostridium cellulolyticum H10 (ZP_01574356.1; e value = 8 3 10 À56 ; 38% identity), to BaeD, a discrete AT from the bacillaene cluster of B. amyloliquefaciens FZB42 (CAG23951.1; e value = 4 3 10 À45 ; 33% identity [Chen et al., 2006] ), and to PedC, a discrete AT encoded in the pederin gene cluster (AAS47559.1; e value = 4 3 10 À40 ; 34% identity [Piel, 2002] ). However, due to lack of a structural model for BryP AT 2 and its closest homologs, the role that specific residues lining the active site pocket play in substrate specificity is more difficult to predict.
Phylogenetic analysis of the amino acid sequences suggests that BryP AT 1 is closely related to AT domains from bacterial FASs (Figure 2 ). These discrete enzymes utilize malonyl-CoA as a substrate for fatty acid biosynthesis (Hopwood and Sherman, 1990) . Other PKS trans-AT domains (MmpC AT 2 , PedD, RhiG AT 2 , LmnG, DifA) form a clade together with BryP AT 1 . Interestingly, BryP AT 2 diverges from these FAS-related AT domains, and forms a clade with another group of trans-AT domains, including MmpC AT 1 (El-Sayed et al., 2003) , RhiG AT 1 (PartidaMartinez and Hertweck, 2007) , PedC (Piel, 2002) , and BaeD (Chen et al., 2006 ), which appears to be more closely related to embedded PKS AT domains (Figure 2 ). While all trans-AT PKSs that have been sequenced to date have a discrete AT domain from the former category (e.g., related to FAS AT), only a few have a discrete AT from the latter category (i.e., PKS-embedded AT). Of those with two or three AT domains (e.g., bryostatin [Sudek et al., 2007] , mupirocin [El-Sayed et al., 2003] , bacillaene [Cheng et al., 2003 ], myxovirescin A1 [Simunovic et al., 2006] , rhizoxin [Partida-Martinez and Hertweck, 2007] , and pederin [Piel, 2002] ), two AT domains are encompassed on a single ORF for most of these clusters. However, it is unclear why some PKS gene clusters contain more than one trans-AT domain. As ''Ca. Endobugula sertula'' remains refractory to laboratory culture, it is not possible to assess function of the two AT domains comprising bryP by traditional gene disruption and complementation assays. Instead, a related surrogate system was employed to test functional rescue of AT activity.
Complementation of P. fluorescens NCIMB 10586 mmpC AT Deletion Mutant by BryP AT 1 and BryP AT 1 AT 2 To test the hypothesis that the two bryP-encoded AT domains retain and display related functions, we assessed mutant complementation in the mupirocin biosynthetic system from P. fluorescens (e.g., production of pseudomonic acid (PA) A [PA-A] [ Figure 1B] ). Of the two AT domains that comprise MmpC, MmpC AT 2 is most similar to BryP AT 1 phylogenetically (44.4% versus 24.1% to BryP AT 2 amino acid identity), while MmpC AT 1 has a higher similarity to BryP AT 2 (Figure 2 ; 28.2% versus 23.5% to BryP AT 1 amino acid identity). Bioinformatic analysis has also revealed that MmpC likely contains a third C-terminal domain of unknown function. In-frame deletion of mmpC-encoded AT 1 results in the reduction of pseudomonic acid A (PA-A) to 13.5% of wild-type (WT) P. fluorescens, while no PA-A is detected in the mmpC AT 2 deletion mutant ( Figure 3A ). The disk-diffusion bioassays showed that antibiotic activity remaining in the MmpC DAT 1 mutant was significant ( Figure 3B ). Complementation of the DmmpC AT 1 mutant by BryP AT 1 resulted in restoration of PA-A to approximately 83% of WT levels in the HPLC assays ( Figure 3A) . Similarly, in the disk-diffusion bioassays, complementation by bryP AT 1 restored bioactivity to approximately 70% of WT levels (controls were roughly 30% of WT levels), and the addition of two different concentrations of isopropyl b-D-1-thiogalactopyranoside (IPTG) (0.1 and 0.5 mM) did not affect the bioactivity of the extract ( Figure 3B ). In contrast, expression of BryP AT 1 AT 2 in the DMmpC AT 1 mutant resulted in much lower production of PA-A. The addition of IPTG resulted in decreased levels of secondary metabolite production, suggesting that higher levels of BryP AT 1 AT 2 can inhibit biosynthesis, possibly due to the formation of a nonfunctional protein-protein complex. However, similar results occurred when plasmid-borne mmpC AT 2 was used to complement this mutant (El-Sayed et al., 2003) , suggesting that intracellular levels of trans-AT may be Minimum evolution tree of amino acid sequences of AT domains from B. neritina-''Ca. Endobugula sertula'' and related PKS and FAS gene clusters. Bootstrap analysis was performed 10,000 times, and nodes with percentages greater than 50% are labeled. Scale bar = 0.1 amino acid substitutions per site. GenBank accession numbers are listed after each sequence, and the sequences utilized in this study are in bold.
important during biosynthesis. Interestingly, neither BryP AT 1 nor BryP AT 1 AT 2 was able to complement the DmmpC AT 2 mutant, an in-frame deletion removing only AT 2 (leaving both AT 1 and the third [unknown] domain of MmpC intact). This result was surprising, since BryP AT 1 and MmpC AT 2 cluster together in the FAS-like PKS trans-AT group. Since such AT domains clearly can retain the ability to cross-complement (but that this does not correlate with the specific phylotype), it appears that there may be no fundamental difference between the activity of the two AT domains except in the ad hoc way that they may have adapted to their genetic and biochemical context.
In Vitro Substrate Preference of BryP
Sequence analysis of the discrete AT domains suggests that BryP AT 1 should utilize malonyl-CoA as a substrate, as it has several amino acids that are thought to be involved in specificity for this precursor substrate (Met126 and Phe200 Streptomyces coelicolor FabD numbering [Keatinge-Clay et al., 2003 ; Figure S1 ]). BryP AT 2 also has Phe200 (similar to ATs that mediate malonyl-CoA transfer), but has Leu126 and Ile56 that are typically found in AT domains selective for methylmalonyl-CoA (Keatinge-Clay et al., 2003) , suggesting that it may use an alternative substrate. We therefore decided to investigate the substrate specificity of the two AT domains comprising BryP, as well as to determine the ability of the AT domains to transacylate carrier proteins and complete PKS modules. AT-mediated transfer is a twostep reaction (Keatinge-Clay et al., 2003) . In the first step, the extender unit substrate (usually either malonyl-CoA or methylmalonyl-CoA) is covalently attached to the active site serine of the AT (termed ''loaded'') and CoASH is released; in the second step, the extender unit undergoes transesterification from the AT active site serine to the phosphopantetheine prosthetic group of the ACP. In order to investigate the activity of BryP with PKS ACPs and modules, a series of gene constructs were cloned into Escherichia coli overexpression vectors, and the purified polypeptides (BryP, as mono-and didomain fusion proteins) employed for in vitro assays (see Supplemental Data for details).
The acyl-CoA substrate loading preference of the BryP variants and their ability to transfer the substrates to an ACP from the bryostatin gene cluster (BryB M7 ACP) was assessed. BryP AT 1 was able to transfer [
14 C]-malonyl-CoA onto holo BryB M7
ACP, but not onto the apo protein ( Figure S2 ). In addition, no radioactivity was detected from the holo BryB M7 ACP, although it is evident that more malonyl-CoA is transferred than methylmalonyl-CoA in the same amount of time (20 min) ( Figure 4B ). In a time course experiment, there was no apparent difference in the amount of labeling of both BryP AT 1 and BryB M7 ACP, suggesting that malonate is not released (e.g., hydrolyzed) from the ACP phosphopantetheine arm after 60 min (data not shown). There was no significant difference in the activity of BryP AT 1 in the range of pH tested (data not shown). In addition, there was no difference detected in the activity of BryP AT 1 at pH 7.4 with and without EDTA and dithioerythritol (DTE). The kinetic parameters of BryP AT 1 transferring varying concentrations of malonyl-CoA to BryB M7 ACP were determined. The K M was calculated to be 7 mM (±0.6 SE) and k cat /K M was 0.1 mM À1 s À1 ( Figure 4C ). Because of the decreased solubility of BryB M7 ACP at high concentrations, kinetic experiments that varied its concentration were not performed. The K M value of BryP AT 1 with malonyl-CoA as the substrate (7 mM) is a little more than five times lower than the value reported for FenF with MycA ACP 2 , but the k cat value is $24 times less than FenF (Aron et al., 2007) . Both the K M and k cat values are much lower than those calculated for the S. coelicolor and E. coli FAS MAT and ACP (Szafranska et al., 2002) , suggesting that, although BryP AT 1 has a low turnover rate, it has a high affinity for malonyl-CoA. Fourier transform ion cyclotron mass spectrometry (FT-ICR MS) was employed to qualitatively confirm the types of substrates loaded from a pool of acyl-CoAs and to verify the predicted active-site serine of BryP AT 1 . Briefly, BryP AT 1 was incubated with an equimolar mixture of malonyl-, methylmalonyl-, acetyl-, and propionyl-CoA, and analyzed intact by FT-ICR MS. Three peaks were detected in the repeating isotope pattern of the loaded BryP AT 1 ( Figure 4D , top panels). For clarity, the mass shift in the +37 charge state is used in the following discussion, although similar shifts in mass were apparent for all charge states observed. Unloaded BryP AT 1 at the expected mass was observed in the sample, as well as BryP AT 1 with a shift in m/z of 2.25 or 83.2 Da, likely due to the addition of malonyl-CoA. Additionally, a shift in m/z of 2.73 in the +37 charge state was observed, correlating to the addition of 101 Da, and the loading of methylmalonyl-CoA. The control reaction resulted in only unloaded BryP AT 1 ( Figure 4D , bottom panels). In a subsequent experiment, BryP AT 1 was subjected to proteolytic digestion prior to FT-ICR MS analysis to ensure that loading occurs on the predicted active site serine residue. A Glu-C-derived peptide, SHKPSYVAGHSLGE, was identified by MS/MS in the malonyland methylmalonyl-loaded forms. A partial tryptic peptide, TQFT QPALYIINALSFLDKIELESHKPSYVAGHSLGEYNALFAAGAFDF LTGLK, was also identified by MS/MS in the malonyl-and methylmalonyl-loaded forms. The predicted active site serine (bold) was determined to be the modified residue in both cases.
LC/MS was used to investigate acyl group transfer from BryP AT 1 to another Bry ACP, BryA M3 ACP ( Figure 1A ). Both proteins were incubated together in the presence or absence (control) of equimolar amounts of acetyl-, malonyl-, methylmalonyl-, and propionyl-CoA. Experiments in the absence of BryP AT 1 showed that the holo ACP did not self-load to an appreciable degree (data not shown). In the presence of BryP AT 1 and the acylCoAs, BryA M3 ACP peaks increased in mass by 5.1 m/z in the +17 charge state, an 86.7 Da mass increase consistent with a preference for malonyl-CoA ( Figure 5 ). An additional peak with a mass shift of 179 Da is observed in the LC-MS data; this is likely a-N-6-phosphogluconoylation, a common posttranslational modification observed on fusion proteins with a 63 His affinity tag (Geoghegan et al., 1999) . This additional peak exhibits the same mass shift and preference as the holo ACP.
Taken together, these data suggest that BryP AT 1 can load both malonyl-and methylmalonyl-CoA (Figure 4 ), but that malonate is preferentially transferred to the Bry ACPs. The preference for malonyl-CoA over methylmalonyl-CoA has been demonstrated for other trans-AT gene clusters. In vitro assays with the myxovirescin gene cluster from Myxococcus xanthus DK1622 trans-AT didomain (TaV) (Simunovic et al., 2006) have shown that TaV AT 2 (which is a FAS-like trans-AT [ Figure 2] ) prefers malonyl-CoA over methylmalonyl-CoA, acetyl-CoA, and propionyl-CoA . In addition, TaV AT 2 was able to acylate both discrete and embedded ACP domains from the gene cluster . No in vitro assays were performed on TaV AT 1 , which is more similar to BryP AT 2 (Figure 2) . The trans-AT associated with the bacillaene cluster in B. subtilis (PksC) (Butcher et al., 2007) , which forms a clade with BryP AT 1 (Figure 2) , was also shown to preferentially load malonyl-CoA over acetyl-CoA and methylmalonylCoA, and transfer malonyl-CoA onto a cognate, discrete ACP (AcpK) (Calderone et al., 2006) .
BryP Exhibits Flexibility for Transferring Malonate onto ACPs
The mono-and didomain constructs of BryP were assayed for their ability to transfer substrates onto an ACP from another PKS (pikromycin PikAIII M5 ACP [Xue et al., 1998 ]), and a peptidyl carrier protein (PCP) from an aminocoumarin (clorobiocin) biosynthetic gene cluster (Pojer et al., 2002) . BryP AT 1 transferred [ 14 C]-malonyl-CoA onto a variety of carrier proteins, including the BryB M7, PikAIII M5 ACPs, as well as the holo (but not the apo) forms of CloN5 ( Figure S2 ). The BryP didomain (BryP AT 1 AT 2 ) and the didomain single mutants BryP AT 1 AT 2 and BryP AT 1 AT 2 were able to catalyze loading of each of the carrier proteins presented. The double mutant BryP AT 1 AT 2 , as expected, did not catalyze acyl transfer to any of the carrier proteins. One BryP AT 2 construct (37) was also able to catalyze transfer of malonyl-CoA to each of the carrier proteins (data not shown). The flexibility of BryP in transferring malonate to ACPs from two PKS gene clusters (bryostatin and pikromycin) was similar to that of FenF, a discrete FAS-like AT in the mycosubtilin gene cluster (Duitman et al., 1999) . FenF did not exhibit significant preference in vitro for the substrate (malonyl-CoA) ACP compared to the loading (palmitoyl-CoA) ACP in MycA (Aron et al., 2007) . Conversely, while BryP was also able to transfer malonate onto a PCP from the clorobiocin biosynthetic gene ( Figure S3 ), FenF was eight times less efficient loading malonylCoA onto one of the PCP domains in MycA (Aron et al., 2007) . Moreover, the discrete AT (LnmG) in the leinamycin gene cluster was not able to load malonyl-CoA onto an excised PCP from that PKS/NRPS gene cluster (Cheng et al., 2003) , suggesting that either the PCP domain is unable to bind to malonyl-CoA, or that the discrete ATs are unable to recognize or interact with the PCP. As both the hybrid PKS/NRPS leinamycin and mycosubtilin gene clusters contain ACP and PCP domains, it would be advantageous for the discrete ATs to discriminate between the two types of carrier proteins to avoid biosynthetic derailment by acylating the incorrect thiolation domain. However, because the bryostatin gene cluster is only composed of PKS modules, BryP may not have evolved to selectively interact with ACP versus PCP domains.
BryP-Catalyzed Acyl Transfer onto PKS Modules from the Pikromycin, Erythromycin, and Bryostatin Gene Clusters A previous study demonstrated the ability of the S. coelicolor FAS MAT to catalyze transfer of malonyl-CoA onto the ACP of an EryAIII module 6 AT mutant (Kumar et al., 2003) . We decided to extend this type of trans-AT substrate delivery analysis using BryP toward a series of PKS modules, including PikAIV M6 (Pik module 6), EryAIII M6, and BryB M4. BryP AT 1 was not able to load malonyl-or methylmalonyl-CoA onto the PikAIV M6 AT module ( Figure 6A ), the native substrate of which is methylmalonyl-CoA (Xue et al., 1998) . The WT PikAIV M6 was able to self-load and transfer methylmalonyl-CoA, but not malonylCoA. Similarly, WT EryAIII M6 was able to self-load methylmalonyl-CoA (its native substrate [Donadio et al., 1991] ) (data not shown), but not malonyl-CoA ( Figure 6B ). In contrast to the PikAIV M6 AT , BryP AT 1 was able to effectively transfer malonyl-CoA onto EryAIII M6 AT ( Figure 6 ). Most significantly, BryP AT 1 was able to transfer [ 14 C]-malonyl-CoA onto the holo form of the native module BryB M4, but was unable to do so onto the apo preparation of BryB M4 ( Figure 6B ). The BryP AT didomain was able to transfer malonyl-CoA onto both EryAIII M6 AT and the native module BryB M4 ( Figures 7A and 7B ). Both single-mutant BryP AT didomain proteins were able to load malonyl-CoA onto these individual modules, although, based on relative signal strengths of the BryP AT 1 AT 2 point mutants, it appears that AT 1 is more active than AT 2 ( Figure 7B , lanes 4, 5, 11, and 12). The BryP AT double mutant was not able to transfer malonyl-CoA onto the module. Neither BryP AT 1 nor the didomain was able to transfer methylmalonyl-CoA onto either EryAIII M6 AT or the native BryB M4 module ( Figure 7C ). Interestingly, BryP AT 2 (37) was able to transfer methylmalonyl-CoA onto the EryAIII M6 AT module, but was unreactive toward BryB M4 ( Figure 7C, lane 7) . In vivo, these trans-ATs are hypothesized to acylate ACP domains that are part of a multidomain module. While the mono-and didomain constructs of BryP were able to transfer malonyl-CoA onto modules BryB M4 and EryAIII M6 AT ( Figures 6B and 7B ), BryP AT 1 was unable to transfer 
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Trans-Acylation in Bryostatin Biosynthesis malonyl-CoA onto PikAIV AT ( Figure 6A ). These data suggest that there may be some specificity regarding the interaction between the trans-AT and the module.
All of the bryostatins characterized to date have two gemdimethyl groups (at C8 and C18; Figure 1 ). The modules that are putatively responsible for the assembly of those regions contain MT domains (M4 and M9) (Sudek et al., 2007) that could add either one or two methyl groups to the a-carbon. We were motivated to investigate the substrate preference of the two AT domains of BryP, as they could possibly load different substrates (malonyl-CoA or methylmalonyl-CoA) onto the ACPs from these modules that could then be methylated either once or twice by the embedded MT enzymatic domains, resulting in the geminal dimethylated carbon atoms. Two other natural products that have gem-C-dimethyl groups are the mixed PKS/NRPS compounds epothilone (Molnar et al., 2000) and yersiniabactin (Gehring et al., 1998) , and both have embedded MT domains within the PKS module, which is responsible for the elongation and modification of the corresponding portion of the molecule. The biosynthetic origins for the methyl groups have been investigated, and, interestingly, two different mechanisms have been described. In yersiniabactin biosynthesis, data from in vivo feeding studies (Gehring et al., 1998) and in vitro assays with purified enzymes (Miller et al., 2002) suggest that the polyketide chain is elongated by malonyl-CoA, and both methyl groups originate from S-adenosyl-methionine. However, in epothilone biosynthesis, several lines of evidence, including feeding studies (Gerth et al., 2000) and bioinformatic analysis of the AT domain substrate preference (Molnar et al., 2000; Petkovic et al., 2008) , support the hypothesis that methylmalonyl-CoA is incorporated into the polyketide chain by the embedded AT, followed by C-methylation on the a-carbon. One of the Bry MT-containing modules was targeted (BryB M4) (Sudek et al., 2007) in efforts to determine the likely mode of methylation. When methylmalonyl-CoA was tested as a substrate, the single BryP AT 2 domain was able to label only EryAIII M6 AT , the natural substrate of which is methylmalonyl-CoA (Donadio et al., 1991) . As neither the BryP didomain nor the BryP AT 1 AT 2 mutant was able to acylate EryAIII M6 AT with methylmalonyl-CoA, having the additional domain (AT 1 ) may interfere with the ability of AT 2 to load the module with methylmalonyl-CoA. However, since BryP was not able to load methylmalonyl-CoA onto BryB M4, it seems more likely that the MT adds two methyl groups as in yersiniabactin biosynthesis. The dimethylation at the C-8 and C-18 positions on the growing bryostatin chain elongation intermediate is consistent with the general malonyl-CoA selectivity of all known trans-AT domains investigated from various Gram-positive, Gram-negative, and microbial symbiont natural product pathways (Nguyen et al., 2008) . This is also consistent with the lack of a methylmalonyl-CoA precursor pool in all known g-proteobacteria that includes the uncultured bacterial symbiont ''Candidatus Endobugula sertula,'' which is responsible for the biosynthesis of the bryostatin anticancer natural products.
SIGNIFICANCE
In this study, we demonstrate that BryP exhibits flexibility when loading malonyl-or methylmalonyl-CoA, but prefers to transfer malonate to excised and modular acyl carrier proteins (ACPs). Furthermore, BryP is able to transfer the predicted extender unit, malonyl-CoA, onto a complete native module from the presumed bryostatin biosynthetic gene cluster. Results from this investigation suggest that the geminal dimethyl groups at C-8 and C-18 on the bryolactone ring system are derived from double C-methylation of a malonate extender unit during chain elongation. While several large polyketide synthase (PKS) gene clusters from uncultivated symbiotic microbes have been cloned and sequenced (Partida-Martinez and Hertweck, 2007; Piel, 2002; Piel et al., 2004) , this is, to our knowledge, the first instance that a large portion of a PKS gene cluster from an uncultivated symbiotic microbe has been overexpressed and demonstrated to function with cognate enzymatic domains. In vivo assays with Pseudomonas fluorescens mupirocin DAT mutants showed that BryP is only able to complement one of the AT domain mutant strains. A number of questions remain to be explored about how these domains physically interact with PKS modules and full PKS polypeptides and megacomplexes. Finally, this is the first step toward demonstrating unequivocally that the assigned Bry metabolic system produces the bryostatins.
EXPERIMENTAL PROCEDURES
Sequence and Phylogenetic Analysis of the AT Domains Shallow and deep bryP sequences (Sudek et al., 2007) were analyzed by BLAST (Altschul et al., 1990) . The amino acid sequences were aligned with the sequences of other trans-AT domains as well as integrated AT domains 
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Trans-Acylation in Bryostatin Biosynthesis from PKS gene clusters using ClustalX (Thompson et al., 1997) . A minimum evolution phylogenetic tree was generated using MEGA version 4 (Tamura et al., 2007) . Subjecting the alignment to alternative algorithms (neighbor joining and maximum parsimony) resulted in similar topology.
Generation of mmpC AT In-Frame Deletion Mutants in the Mupirocin Producer, P. fluorescens NCIMB10856 Construction of an in-frame deletion in MmpC AT 2 has been previously described (El-Sayed et al., 2003) . Deletion of MmpC AT 1 was carried out with suicide plasmid pJHAT101 that contains an mmpC deletion of 907 bp (23,214-24,120 bp inclusive, database numbering). This creates a frame shift in the remaining MmpC AT 1 sequence such that a 24 codon ORF will deliver ribosomes to the ribosome binding site and ATG start codon at the beginning of the AT 2 domain of mmpC. Production of pseudomonic acids by this mutant was verified, suggesting that MmpC AT 2 was still functional.
Construction of P. fluorescens expression plasmids.
For in trans expression of bryostatin ATs in P. fluorescens AT deletion strains, domains were cloned into the IncQ vector pJH10 under the control of the tac promoter (El-Sayed et al., 2003) . BryP AT 1 was restricted from pNL020 (Table  S1 ) and ligated into pJH10 to give pJS261. The AT didomain (BryP AT 1 AT 2 ) was PCR amplified from a fosmid subclone (MM5_2_BO7) using primers BryP_AT1_F and BryP_AT2_R (Table S2) , and cloned into pJH10 to give pJS262. Inserts were verified by sequencing. Complementation plasmids were introduced into the MmpC mutant strains of P. fluorescens by conjugation with plasmid-bearing E. coli S17-1, as described previously (Hothersall et al., 2007) . Positive colonies were screened for metabolite production. Antibiotic disk-diffusion bioassays using B. subtilis cultures were used to screen for mupirocin, which is a mixture of PA, dominated by PA-A (90%). Direct quantification of PA-A was performed by HPLC analysis of strain extracts. Both experiments were run in duplicate.
In Vitro Substrate Preference of BryP Radioactive assays of BryP activity To determine the ability of BryP to acylate various carrier proteins and PKS modules, each was individually incubated with the BryP proteins and radiolabeled substrate (see cloning and overexpression details in Supplemental Data). In general, the reactions were run in 50 mM HEPES buffer, pH 7.4, 5-10 mM carrier protein or module protein, 1-8 mM BryP protein, and 0.4-0.5 mM substrate. The enzymes were equilibrated at room temperature (RT) for 5 min before the substrate was added.
Reactions proceeded for 5-20 min at RT, and were quenched by the addition of 23 SDS-PAGE loading buffer with no reducing agent. The samples were mixed and loaded onto SDS-PAGE gels. After electrophoresis, the gels were stained with either Coomassie blue or SimplyBlue (Invitrogen) stains, and destained. The gels were dried (BioRad), and placed into a phosphoimager cassette (Amersham Biosciences). After 5 days, the phosphoimager screen was scanned, and the images were analyzed.
To determine the substrate preference of BryP AT 1 , radiolabeled and unlabeled malonyl-and methylmalonyl-CoA were mixed in separate reactions. ]-methylmalonyl-CoA (0.5 mM) to BryB M7 ACP (20 mM). As the BryP didomain and BryP AT 2 constructs could not be purified to homogeneity, their concentration could not be determined accurately. A 6 ml aliquot of the eluted protein from the nickel-nitrilotriacetic acid column was used in each reaction; BryP AT 1 was added to a final concentration of 4 mM. The reaction was quenched after 20 min. In a time-course experiment, 7.5 mM of BryB M7 ACP was incubated with 1 mM BryP AT 1 and 0.4 mM [
14 C]-malonyl-CoA, and the reactions were quenched after 5, 10, 15, 30, and 60 min. A protein precipitation assay was used to quantify the activity of BryP AT 1 in the presence of BryB M7 ACP. The activity of BryP AT 1 was determined in HEPES buffer (50 mM) with different pH values ranging from 6.0 to 9.2. These assays were conducted by incubating BryP AT 1 (1 nM) with [
14 C]-malonyl-CoA (0.1 mM) and BryB M7 ACP (50 mM), and measuring the amount of radiolabel bound to BryB M7 ACP after acid precipitation and scintillation counting based on the method previously described . EDTA and DTE (2 mM each) was added to each reaction; one duplicate set of reactions at pH 7.4 was run without EDTA or DTE to determine if they affected BryP AT 1 activity. The reactions and no-enzyme controls (bovine serum albumin [BSA] 10 mg/ml) were run in duplicate. The reaction mixture was equilibrated at RT for 5 min before the enzyme (or BSA) was added, and the reaction proceeded at RT for 5 min. The amount of radiolabel incorporation versus background was compared among the duplicate reactions at the different pHs, and between the pH 7.4 samples run with and without DTE and EDTA. The reaction kinetics of BryP AT 1 with malonyl-CoA and purified BryB M7 ACP were determined using the TCA precipitation method at pH 7.4. The final concentration of BryP AT 1 was 1 nM, and the final concentration of BryB M7 ACP was 50 mM. The concentration of [
14 C]-malonyl-CoA varied from 0.2 to 250 mM. The loading reaction proceeded for 5 min on ice, after which the reaction was quenched. The reaction and controls (1 nM BSA) were performed in triplicate. Kinetic parameters were not obtained for varying concentrations of BryB M7 ACP, as this protein would precipitate out of solution at high concentrations.
FT-ICR MS analysis of BryP AT 1 BryP AT 1 (5 mM) was reacted with a pool of 250 mM acetyl-, malonyl-, methylmalonyl-, and propionyl-CoA in 50 mM HEPES (pH 7) buffer and 1 mM TCEP. After incubation for 30 min, samples were acidified with 1% formic acid. Intact protein samples were desalted with Handee Microspin columns (Pierce) packed with 20 ml of 300 Å polymeric C4 resin (Vydac). Samples were loaded onto the columns and washed with 30 column volumes of 0.1% formic acid prior to elution with 10 column volumes of 50% acetonitrile plus 0.1% formic acid. Intact protein samples were analyzed by an FT-ICR MS (APEX-Q with Apollo II ion source and actively shielded 7T magnet; Bruker Daltonics). Data was gathered from m/z 250-2000 utilizing direct infusion electrospray ionization in positive ion mode. Electrospray was conducted at 3600 V with 24-60 scans per spectra utilizing 0.5 s external ion accumulation in the hexapole prior to analysis in the FT-ICR using a loop value of 15. All CID MS/MS was performed external to the FT-ICR cell with quadrapole mass selection. In order to confirm that the modification occurred on the active site serine, BryP AT 1 was then subjected to proteolytic digestion after reaction with the acyl CoA pool and FT-ICR MS analysis. Glu-C (Worthington Biochemical) or trypsin (Promega) (1/100 [w/w]) was added to the samples, and digestion proceeded for 4 hr at 37 C. Proteolytic peptides were desalted as above with the exception that C18 resin was utilized. FT-ICR MS analysis was performed as above, except that the loop value was 4 and the ion accumulation time was 1 s. LC-MS analysis of BryA M3 ACP BryP AT 1 (2 mM) and BryP AT 1 (20 mM) were reacted with a pool of 250 mM acetyl-, malonyl-, methylmalonyl-, and propionyl-CoA. Reactions were incubated for 45 min in 50 mM HEPES (pH 7) and 1 mM TCEP, and were quenched by diluting 23 in 6 M urea, 100 mM HEPES (pH 6). A 10 ml sample of this mixture was analyzed by LC-MS with a Shimadzu LCMS-2010EV (Columbia, MD) after separation on a PLRP-S 2 3 50 mm, 4000 Å , 8 mm polymeric RP-HPLC column (Varian, Palo Alto, CA) heated to 50 C. Samples were desalted online for 5 min with 95% buffer A (98.9% water, 1% acetonitrile, 0.1% formic acid) and 5% buffer B (1% water, 98.9% acetonitrile, and 0.1% formic acid), followed by gradient elution over 20 min. Profile mode data was gathered from m/z 400-2000 utilizing electrospray ionization in positive ion mode.
BryP Transfer to Other ACPs
The ability of BryP AT 1 to acylate a variety of carrier proteins was assayed by in vitro incubation of the proteins with radiolabeled substrates followed by SDS-PAGE autoradiography, as described previously. Purified BryP AT 1 (2 mM) was incubated with both apo and holo BryB M7 ACP (10 mM), 0. BryP concentrations added were 4 mM BryP AT 1 , 0.9 mg/ml BryP didomains, and 0.6 mg/ml of BryP AT 2 (37). The reaction proceeded for 10 min at RT. tested at 5 and 10 mM, and PikAIV AT was tested at 10 mM. BryP AT 1 (2 mM) was added, and after equilibration, either radiolabeled substrate was added (0.4 mM). After 5 min at RT, the reaction was quenched. Next, BryP AT 1 was assayed with malonyl-CoA and EryAIII M6 AT or BryB M4. BryP AT 1 (4 mM) and [
14 C]-malonyl-CoA (0.5 mM) were incubated with EryAIII M6 AT (10 mM) for 10 min at RT. The amylose resin elutions of BryB M4 were used without further purification; the pooled fractions were assayed at a final concentration of 2.2 mg/ml total (holo BryB M4) or 1.1 mg/ml (apo BryB M4).
The other BryP constructs were tested for their ability to load both malonyland methylmalonyl-CoA onto the EryAIII M6 AT and BryB M4 modules. The final concentration of EryAIII M6 AT was 5 mM, that of BryP AT 1 was 4 mM, and that of substrate was 0.5 mM. The final concentration of the BryB M4 preparation was 3.3 mg/ml, that of the BryP AT didomain preparations was 0.9 mg/ ml, and that of BryP AT 2 (37) was 0.6 mg/ml. The reactions were quenched after 15 min at RT.
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